All In Biotech

Drug Trial Radar · NCT03447769

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)

Last checked: Nov 20, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,382 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,382

Actual

Start

Mar 16, 2018

Primary completion

Mar 17, 2022

Study completion Feb 7, 2023

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study was to compare the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages II -IIIA according to the 8th edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) and the subset of IIIB (T\>5cm N2 disease) completely resected (R0) non-small cell lung cancer (NSCLC).

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • CanakinumabDrug

    200 mg of canakinumab administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Canakinumab solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.

  • PlaceboDrug

    Placebo administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Placebo solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease Free Survival (DFS) by Local InvestigatorTime frame: Up to approximately 4 years

Locations

283 sites in 41 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group .

    Fayetteville, Arkansas

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California

  • University of California at Los Angeles

    Los Angeles, California

  • VA Palo Alto Health Care System CRLX030A2301

    Palo Alto, California

  • Sansum Clinic

    Santa Barbara, California

  • Rocky Mountain Cancer Centers Denver-Mdtn(Bone&MarrowTransp)

    Longmont, Colorado

  • Florida Cancer Specialists

    Fort Myers, Florida

  • Advanced Medical Specialties Drug Ship - 2

    Miami, Florida

  • Florida Cancer Affiliates of Ocala

    Ocala, Florida

  • Florida Cancer Specialists North

    St. Petersburg, Florida

  • Florida Cancer Specialists

    West Palm Beach, Florida

  • Rush University Medical Center Regulatory

    Chicago, Illinois

  • Cancer Center of Kansas Dept.ofCancerCtr.ofKansas

    Wichita, Kansas

  • VA Nebraska-W IA Health Care System .

    Omaha, Nebraska

  • Louis Stokes Cleveland Department of Veterans Affairs MC .

    Cleveland, Ohio

  • Oncology Associates of Oregon, PC

    Eugene, Oregon

  • Chattanooga Oncology and Hematology Associates PC Chattanooga Oncology

    Chattanooga, Tennessee

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Texas Oncology MamieMcFaddenWardCtr

    Dallas, Texas

  • Virginia Cancer Specialists Fairfax Northern Virginia

    Fairfax, Virginia

  • Oncology and Hematology Associates of Southwest Virginia Inc .

    Salem, Virginia

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Mar del Plata, Buenos Aires, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    Rosario, Sante Fe, Argentina

  • Novartis Investigative Site

    Graz, Austria

  • Novartis Investigative Site

    Klagenfurt, Austria

  • Novartis Investigative Site

    Krems, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Londrina, Paraná, Brazil

  • Novartis Investigative Site

    Teresina, Piauí, Brazil

  • Novartis Investigative Site

    Barretos, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Edmonton, Alberta, Canada

Showing 40 of 283 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.